Certara, Inc. CERT
12.04 USD -0.09 (-0.70%)
Nov 11, 2026, 1:21 PM EST
11.91 Day range 12.38
4.45 52-week range 12.61
- YTD
- +36.66%
- 1 year
- +40.33%
News
seekingalpha.com Certara, Inc. (CERT) Q3 2026 Earnings Call Transcript Certara, Inc. ( CERT ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Jon Resnick - CEO & Director Faiz Mohammed - Interim CFO, Senior VP of Finance, Treasurer and Principal…
benzinga.com Barclays Maintains Equal-Weight on Certara, Raises Price Target to $12 Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Equal-Weight and raises the price target from $9 to $12.
marketbeat.com Certara Q3 Earnings Call Highlights Certara NASDAQ: CERT reported 4% revenue growth in the third quarter of 2026 as double-digit software growth offset a decline in services, while cost reductions and a favorable sales mix helped lift…
zacks.com Certara, Inc. (CERT) Tops Q3 Earnings and Revenue Estimates Certara, Inc. (CERT) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.14 per share a year ago.
benzinga.com Certara Q3 2026 Earnings Call Transcript Certara (NASDAQ:CERT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Certara Narrows FY2026 Adj EPS Guidance from $0.31-$0.36 to $0.31-$0.34 vs $0.34 Est; Revenue for 2026 FY is expected to be up by 2% to 3% YoY Certara (NASDAQ:CERT) narrows FY2026 Adj EPS guidance from $0.31-$0.36 to $0.31-$0.34 vs $0.34 analyst estimate. Revenue for 2026 FY is expected to be up by 2% to 3% YoY
globenewswire.com Certara Reports Third Quarter 2026 Financial Results Certara delivers a solid quarter with double-digit software revenue growth Updates 2026 financial outlook Appoints Grant Peterson Chief Product Officer Company to host conference call and webcast…
benzinga.com Keybanc Maintains Overweight on Certara, Raises Price Target to $12 Keybanc analyst Scott Schoenhaus maintains Certara (NASDAQ:CERT) with a Overweight and raises the price target from $9 to $12.
benzinga.com TD Cowen Maintains Buy on Certara, Raises Price Target to $11 TD Cowen analyst Brendan Smith maintains Certara (NASDAQ:CERT) with a Buy and raises the price target from $9 to $11.
benzinga.com Barclays Maintains Equal-Weight on Certara, Raises Price Target to $9 Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Equal-Weight and raises the price target from $7.5 to $9.
benzinga.com UBS Downgrades Certara to Neutral, Maintains Price Target to $10 UBS analyst Kevin Caliendo downgrades Certara (NASDAQ:CERT) from Buy to Neutral and maintains the price target from $10 to $10.
benzinga.com Barclays Maintains Equal-Weight on Certara, Raises Price Target to $7.5 Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Equal-Weight and raises the price target from $6.5 to $7.5.
benzinga.com Transcript: Certara Q2 2026 Earnings Conference Call Certara (NASDAQ:CERT) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. Adagio Medical Holdings…
benzinga.com Certara Lowers FY2026 Adj EPS Guidance from $0.35-$0.41 to $0.31-$0.36 vs $0.38 Est; Lowers FY2026 Sales Guidance from $395.000M-$405.000M to $367.000M-$382.000M vs $398.585M Est Certara (NASDAQ:CERT) lowers FY2026 Adj EPS guidance from $0.35-$0.41 to $0.31-$0.36 vs $0.38 analyst estimate. Lowers FY2026 sales outlook from $395.000 million-$405.000 million to $367.000…- benzinga.com Certara Q2 Adj. EPS $0.08 Misses $0.09 Estimate, Sales $93.271M Miss $98.392M Estimate Certara (NASDAQ:CERT) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.09 by 11.11 percent. This is unchanged from the same period last year. The…
benzinga.com Consumer Tech News (July 6-10): Micron Plans $250B US Expansion, Apple Signs $30B Broadcom Deal & More Apple partners with Broadcom on a multiyear agreement exceeding $30 billion to develop custom silicon and advanced connectivity technologies in America.
benzinga.com Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives Nvidia expands its life sciences AI ecosystem through a Certara partnership and QwikAgents' entry into its developer program.- benzinga.com Certara Partners With NVIDIA To Advance Its Open Integrated AI Platform, Unifying Scientific Software, Regulatory Expertise, And Proprietary Datasets With AI-First, Agentic Frameworks Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, is partnering with NVIDIA to advance Certara's open integrated AI platform, unifying its scientific software,…
benzinga.com Franklin Covey Cuts Revenue Forecast, Joins Ouster And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session US stock futures mixed, Franklin Covey Co drops 19.7% after lowering revenue guidance. Other stocks moving lower in pre-market trading.- benzinga.com Craig-Hallum Maintains Hold on Certara, Lowers Price Target to $8 Craig-Hallum analyst Matthew Hewitt maintains Certara (NASDAQ:CERT) with a Hold and lowers the price target from $10 to $8.
- benzinga.com BMO Capital Maintains Market Perform on Certara, Lowers Price Target to $6 BMO Capital analyst Sean Dodge maintains Certara (NASDAQ:CERT) with a Market Perform and lowers the price target from $7 to $6.
- benzinga.com Barclays Maintains Equal-Weight on Certara, Lowers Price Target to $6.5 Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Equal-Weight and lowers the price target from $8 to $6.5.
- benzinga.com Stephens & Co. Maintains Overweight on Certara, Lowers Price Target to $9 Stephens & Co. analyst Jeff Garro maintains Certara (NASDAQ:CERT) with a Overweight and lowers the price target from $10 to $9.
- benzinga.com Morgan Stanley Maintains Equal-Weight on Certara, Lowers Price Target to $10 Morgan Stanley analyst Sean Laaman maintains Certara (NASDAQ:CERT) with a Equal-Weight and lowers the price target from $11 to $10.
- benzinga.com Baird Maintains Neutral on Certara, Lowers Price Target to $6 Baird analyst Joe Vruwink maintains Certara (NASDAQ:CERT) with a Neutral and lowers the price target from $7 to $6.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com S&P 500 Tops 7,400 As Copper Hits Record Highs: Stock Market Today Small caps lead a mixed Wall Street session as Trump rejects Iran's peace response, sending crude back above $97, copper to a record and silver up 7%.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Earnings Scheduled For May 11, 2026 - benzinga.com Certara Lowers FY2026 Adj EPS Guidance from $0.44-$0.48 to $0.35-$0.41 vs $0.45 Est; Lowers FY2026 Sales Guidance from $418.800M-$435.552M to $395.000M-$405.000M vs $425.854M Est Certara (NASDAQ:CERT) lowers FY2026 Adj EPS guidance from $0.44-$0.48 to $0.35-$0.41 vs $0.45 analyst estimate. Lowers FY2026 sales outlook from $418.800 million-$435.552 million to $395.000…
benzinga.com Certara Q1 Adj. EPS $0.09 Misses $0.11 Estimate, Sales $106.900M Beat $106.095M Estimate Certara (NASDAQ:CERT) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.11 by 18.18 percent. This is a 35.71 percent decrease over earnings of $0.14 per…- benzinga.com Altasciences And Certara Announce Strategic Partnership To Accelerate Early-Phase Development Programs Altasciences, a fully integrated drug development solution company, andCertara (NASDAQ:CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to…
benzinga.com Certara Strategic Business Divestiture Comes At Right Time, Says Analyst Certara stock rises after $135 million divestiture to Veristat as analysts weigh MIDD focus and improving biopharma demand.- benzinga.com Keybanc Maintains Overweight on Certara, Lowers Price Target to $8 Keybanc analyst Brandon Nispel maintains Certara (NASDAQ:CERT) with a Overweight and lowers the price target from $10 to $8.
benzinga.com Forecasting The Future: 7 Analyst Projections For Certara 
benzinga.com Barclays Downgrades Certara to Equal-Weight, Maintains Price Target to $8 Barclays analyst Luke Sergott downgrades Certara (NASDAQ:CERT) from Overweight to Equal-Weight and maintains the price target from $8 to $8.- benzinga.com Barclays Maintains Overweight on Certara, Lowers Price Target to $8 Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Overweight and lowers the price target from $13 to $8.
benzinga.com Earnings Breakdown: Certara Q4 - benzinga.com Certara Q4 Adj. EPS $0.09 Misses $0.11 Estimate, Sales $103.600M Beat $103.193M Estimate Certara (NASDAQ:CERT) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.11 by 20.35 percent. This is a 40 percent decrease over earnings of $0.15 per…
- benzinga.com Earnings Scheduled For February 26, 2026
benzinga.com Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter - benzinga.com Keybanc Maintains Overweight on Certara, Lowers Price Target to $12 Keybanc analyst Scott Schoenhaus maintains Certara (NASDAQ:CERT) with a Overweight and lowers the price target from $13 to $12.
- benzinga.com Deep Dive Into Certara Stock: Analyst Perspectives (6 Ratings)
benzinga.com Earnings Scheduled For November 6, 2025 
benzinga.com RH Posts Downbeat Results, Joins Frequency Electronics, Tronox And Other Big Stocks Moving Lower In Friday's Pre-Market Session - benzinga.com Earnings Scheduled For August 6, 2025
- benzinga.com Earnings Scheduled For May 5, 2025
benzinga.com These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio? Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty.
benzinga.com Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday